Contact Us

102 First Street S
Kalona, IA 52247
USA
COMPANY CONTACT
Shannon Webb
Channel Marketing Lead
319-248-6569
shannon.webb@civco.com

More »

News Releases

CIVCO Next Generation Ultrasound Guide Now Available for GE Healthcare, Philips, and Toshiba
Verza™ guidance system designed to improve user experience, expand clinical versatility, and provide confident outcomes

Coralville, Iowa (November 17, 2017) – CIVCO Medical Solutions will exhibit its latest guidance technology at the Radiological Society of North America (RSNA) annual conference in Chicago November 26 – December 1, 2017. The Verza guidance system is designed to deliver unmatched versatility, enhanced user experience, and confident clinical outcomes for diagnostic and therapeutic ultrasound-guided interventions.

“Verza and VerzaLink™ were developed with input from leading clinicians around the world, with a goal of making ultrasound-guided interventions simpler while expanding the clinical utility of ultrasound guidance systems,” said Alexas Swartz, Director of Marketing at CIVCO. “We believe Verza, in combination with leading ultrasound equipment, will significantly enhance the clinician’s experience using guides.”

A key feature of the Verza system is its direct transducer attachment in combination with VerzaLink, a proprietary locating feature designed onto the ultrasound transducer, eliminating the need for a custom bracket attachment and providing an ideal profile and position on the ultrasound probe. Additionally, VerzaLink reduces time and costs associated with bracket set-up, cleaning, storage, and maintenance.

The Verza system was developed to meet the needs of clinicians accustomed to fixed-angle guidance as well as those who prefer a free-hand technique. Offering a selection of five potential approach angles, the Verza guide provides an optimal pathway for a wide assortment of anatomical targets. With 14 instrument inserts, ranging in size from 25 gauge to 12 French, Verza is designed for compatibility with the market’s largest range of interventional devices.

Building on the improvements of previous CIVCO offerings such as Infiniti Plus™ and the Ultra-Pro™ family of products, Verza delivers improved flexibility, optimal stability, increased accuracy and more efficient functionality while minimizing blind zone and unguided needle length. All of this provides the benefits of decreased procedure time and fewer complications resulting from poor instrument visibility.

Verza is now available for GE Healthcare LOGIQ E9 XDclear 2.0, Philips EPIQ with Evolution 4.0, and Toshiba iAplio iSeries i700, i800, and i900 systems. The 8MC1 (PVT-482BT) ultrasound transducer by Toshiba is also the world’s first ultrasound transducer with VerzaLink. CIVCO is developing numerous Verza and VerzaLink solutions with other leading ultrasound equipment for 2018 release.

Visit www.civco.com/verza to learn more.

About CIVCO

CIVCO Medical Solutions has over 35 years of experience and offers cutting-edge medical technology to a diverse group of medical professionals. CIVCO designs and manufactures accessories for use in diagnostic and therapeutic imaging and interventional procedures with a strong focus on ultrasound. CIVCO’s specialties include: infection control (ultrasound and CT covers to high-level disinfection systems for ultrasound probes), needle and device guidance, and electromagnetic needle tracking. In March 2016, CIVCO acquired PCI Medical, a market leader in ultrasound transducer high-level disinfection. With the addition of high-level disinfection to our product portfolio, CIVCO is a trusted infection control partner to help clinicians maintain compliance. Corporate information is available at WWW.CIVCO.COM.

For more information or product images, please contact:

Shannon Webb

CIVCO Medical Solutions
Tel: 319.248.6569
shannon.webb@civco.com

COPYRIGHT © 2017. CIVCO IS A REGISTERED TRADEMARK OF CIVCO MEDICAL SOLUTIONS. VERZA, VERZALINK, INFINITI PLUS, AND ULTRA-PRO ARE TRADEMARKS OF CIVCO. ALL PRODUCTS MAY NOT BE LICENSED IN ACCORDANCE WITH CANADIAN LAW. 2016C-2937 REV 2